• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Pioneering precision: GE HealthCare aims to elevate clinical care through total body PET/CT technology with Stanford Medicine

    6/19/25 12:00:00 PM ET
    $GEHC
    Medical Electronics
    Health Care
    Get the next $GEHC alert in real time by email
    • GE HealthCare and the Department of Radiology at Stanford Medicine aim to explore total body positron emission tomography/computed tomography (PET/CT) technology for new clinical pathways to help improve patient outcomes.
    • Total body PET/CT technologyi is designed with the goal of supporting personalized medicine practices like theranostics, improve healthcare system efficiency, and provide scalable solutions for imaging practices and healthcare facilities.

    Building on a collaboration that spans more than three decades, GE HealthCare has renewed its research collaboration with Stanford Medicine – with one of their key intentions being the development and research of innovative total body PET/CT technology.i This effort is expected to explore new clinical pathways and help enhance patient outcomes through innovative imaging solutions.

    "PET/CT has revolutionized the way we understand and treat disease by allowing us to visualize biological processes at the cellular level," explains Dr. Quynh-Thu Le, interim Chair of the Department of Radiology, Stanford Medicine. "With total body PET/CT, we can explore new frontiers. Not only do we expect it will be faster, but we also believe it will fundamentally expand what is possible in translational research."

    Molecular imaging – and specifically the utilization of PET/CT scanners – offers opportunities for precision care across various disease states. It supports theranostics in oncology for advanced prostate cancer treatment, helps streamline radiation oncology workflows, aids in beta amyloid imaging for Alzheimer's evaluation and monitoring, and assists in myocardial perfusion evaluation for diagnosing coronary artery disease. Unlike other imaging procedures, PET/CT technology visualizes, characterizes, and quantifies biological processes at the cellular level, aiding in early disease identification, detailed assessment, and treatment planning. It is a non-invasive solution, providing critical insights that help enhance patient care and can support accelerated drug development.

    "This technology is designed to offer a level of sensitivity and spatial resolution that can change how we design and conduct molecular imaging studies," adds Dr. Andrei Iagaru, Division Chief of Nuclear Medicine and Molecular Imaging, Stanford Medicine. "For example, such technological characteristics can create opportunities to reduce anesthesia use in pediatric imaging by dramatically shortening scan times and enable the exploration of dual-tracer studies and early diagnosis with far greater precision. Total body PET/CT technology is an ideal tool to evaluate biodistribution and dosimetry of new PET radiopharmaceuticals in our first human studies."

    Knowing the potential of this technology, researchers at Stanford Medicine and engineers at GE HealthCare aim to advance a next-generation PET/CT designed to provide new opportunities to improve diagnosis, staging, therapeutic planning, and evaluation of treatment response across various care pathways. By leveraging the technology's capabilities, both institutions believe it has the potential to drive new clinical pathways, expedite the development and translation of new diagnostic and therapeutic agents, support existing molecular imaging and theranostics applications, and promote enhanced healthcare system efficiency.

    "The high throughput we anticipate from this technology could ultimately help improve access for our patients and reduce wait times to their next appointment," says Dr. Erin Grady, incoming Division Chief of Nuclear Medicine and Molecular Imaging, Stanford Medicine.

    GE HealthCare's total body PET/CT innovation

    In collaboration with a select group of leading healthcare institutions around the world, GE HealthCare aims to demonstrate how total body PET/CT imaging can overcome barriers that previously hindered widespread adoption of PET/CT beyond oncology. This initiative seeks to expand the use of PET with the goal of leveraging ultra-high sensitivity total body PET/CT technology to push the boundaries of oncology by significantly reducing scan time and the injected dose – important considerations for all patients, but particularly vulnerable patients like pediatrics, where ultra-fast scans can allow reduction in anesthesia and sedation in children.

    To support this advanced research, encourage new discoveries, and meet growing clinical demands, GE HealthCare designed its total body PET/CT technology with the goal of enabling ultra-low dose scans; fast acquisitions; multi organ dynamic imaging; and dual tracer imaging. All important factors that help improve diagnosis confidence. In parallel, the technology aims to improve healthcare system efficiency by enhancing clinical workflows, supporting routine clinical practice, and improving operational efficiency.

    "At GE HealthCare, innovation is in our DNA. Our total body PET/CT technology represents the next chapter in our enduring commitment to advancing medical imaging," adds Jean-Luc Procaccini, President & CEO, Molecular Imaging and Computed Tomography, GE HealthCare. "We're proud to collaborate with world-class institutions to explore new clinical frontiers in oncology and beyond. Together with our MIM software solutions, we're designing flexible, AI-enhanced tools that not only aim to enhance diagnostic confidence and operational efficiency but also help clinicians deliver more precise, personalized care that can truly improve patient outcomes."

    GE HealthCare has a long-standing history of and commitment to pioneering next-generation imaging technology. From the first commercially available PET/CT solution, Discovery LS,ii to the development of the first silicon-based photon counting computed tomography (CT) prototype,iii GE HealthCare continues to push the boundaries of medical imaging for the benefit of clinicians and patients worldwide.

    As such, GE HealthCare is at the forefront of driving a connected healthcare transformation and revolutionizing precision care.

    For more information on GE HealthCare's impressive Molecular Imaging portfolio, visit gehealthcare.com.

    About GE HealthCare Technologies Inc.

    GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

    GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™.

    Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

    ____________________

    i Technology in development. Not for sale. Not cleared or approved by the U.S. FDA or any other global regulator for commercial availability.

    ii Hicks, Rj & Lau, Ewf & Binns, Ds. (2007). Hybrid imaging is the future of molecular imaging. Biomedical imaging and intervention journal. 3. e49. 10.2349/biij.3.3.e49.

    iii GE HealthCare. "Photon Counting CT." GE HealthCare. Accessed June 10, 2025. https://www.gehealthcare.com/products/computed-tomography/photon-counting-ct.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250619733219/en/

    GE HealthCare Media Contact:

    Margaret Steinhafel

    M +1 608 381 8829

    [email protected]

    Get the next $GEHC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GEHC

    DatePrice TargetRatingAnalyst
    5/5/2025$73.00Sell → Neutral
    UBS
    3/11/2025$85.00 → $100.00Neutral → Buy
    Goldman
    1/8/2025$95.00 → $103.00Hold → Buy
    Jefferies
    9/26/2024$84.00 → $74.00Neutral → Sell
    UBS
    9/18/2024$100.00Neutral → Buy
    BTIG Research
    9/9/2024$90.00Neutral
    JP Morgan
    8/6/2024$100.00Buy
    Stifel
    5/30/2024$87.00Neutral
    Goldman
    More analyst ratings

    $GEHC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GE HealthCare launches new advanced digital X-ray system to enable access and increase efficiency in high throughput settings

      Definium™ Pace Select ET, a new floor-mounted digital X-ray system, enables access to affordable, high-quality medical imaging technology while easing workflow burdens in high-volume environments This new X-ray system, designed to act as a personal assistant for technologists, provides automation of in-room workflows and motorization of manual, repetitive tasks to increase throughput and reduce technologist learning curve GE HealthCare (NASDAQ:GEHC), today announced commercial availability of an advanced floor-mounted digital X-ray system, Definium™ Pace Select ET1, designed to deliver high-image quality and optimize efficiency in highly demanding environments while enhancing access

      7/24/25 12:30:00 PM ET
      $GEHC
      Medical Electronics
      Health Care
    • GE HealthCare drives growth with investment in AI-enabled medical devices and tops FDA's list of AI authorizations for 4th Year with 100

      Increased R&D investments to integrate AI on devices across disease states designed to boost productivity, efficiency, and diagnostic confidence for healthcare professionals, and drive the company's long-term growth Milestone advances GE HealthCare's goal of attaining more than 200 authorizations by 2028 GE HealthCare (NASDAQ:GEHC) has topped a U.S. Food and Drug Administration (FDA) list of AI-enabled medical device authorizations for the fourth year in a row with 100 listed authorizations to date in the U.S. This milestone reflects GE HealthCare's continued research and development (R&D) investment and focus on developing AI solutions to advance precision care by enhancing medica

      7/23/25 8:00:00 AM ET
      $GEHC
      Medical Electronics
      Health Care
    • Healthcare's $110B AI Surge Is Picking Up Speed--and It's Just the Beginning

      USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- As artificial intelligence reshapes the future of medicine, understanding how patients actually feel about it is becoming just as critical as the technology itself. A new study published in Nature introduced an "AI Affinity Score" to measure patient comfort with AI in clinical settings—showing that education level and region heavily influence acceptance. The findings suggest that personalizing AI integration based on patient attitudes can enhance care quality and satisfaction. That kind of insight is already guiding investor attention toward emerging opportunities in a secto

      7/8/25 9:34:00 AM ET
      $CI
      $GEHC
      $IQV
      $WAY
      Medical Specialities
      Health Care
      Medical Electronics
      Biotechnology: Commercial Physical & Biological Resarch

    $GEHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Saccaro James covered exercise/tax liability with 9,712 shares, decreasing direct ownership by 14% to 61,832 units (SEC Form 4)

      4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

      6/3/25 4:08:47 PM ET
      $GEHC
      Medical Electronics
      Health Care
    • Director Lavizzo-Mourey Risa J was granted 3,092 shares, increasing direct ownership by 44% to 10,157 units (SEC Form 4)

      4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

      5/30/25 6:05:52 PM ET
      $GEHC
      Medical Electronics
      Health Care
    • Director Lesjak Catherine A was granted 3,092 shares, increasing direct ownership by 51% to 9,116 units (SEC Form 4)

      4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

      5/30/25 6:00:12 PM ET
      $GEHC
      Medical Electronics
      Health Care

    $GEHC
    Leadership Updates

    Live Leadership Updates

    See more
    • PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

      BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

      6/2/25 8:00:00 AM ET
      $GEHC
      $LNTH
      Medical Electronics
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions

      GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa

      4/9/25 9:00:00 AM ET
      $GEHC
      Medical Electronics
      Health Care
    • GE HealthCare's MIM Software collaborates with Elekta to help enhance radiation therapy treatments and improve patient outcomes

      Collaboration has always been important in the healthcare industry, but in this era of digital health, teamwork across institutions has become essential Enhancing Elekta's radiation therapy offerings with GE HealthCare's MIM Software medical imaging management solutions will help drive greater benefits for global healthcare systems This new collaboration complements GE HealthCare and Elekta's existing global commercial collaboration agreement, which enables the two companies to provide hospitals and cancer patients a comprehensive radiation therapy offering across imaging and treatment Weeks after closing its acquisition of MIM Software – a global provider of medical imaging analy

      4/22/24 7:07:00 AM ET
      $GEHC
      Medical Electronics
      Health Care

    $GEHC
    Financials

    Live finance-specific insights

    See more
    • GE HealthCare to announce second quarter 2025 results on July 30, 2025

      GE HealthCare (NASDAQ:GEHC) will announce its second quarter 2025 financial results before the market opens on Wednesday, July 30, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical techno

      7/7/25 8:00:00 AM ET
      $GEHC
      Medical Electronics
      Health Care
    • GE HealthCare announces cash dividend for second quarter of 2025

      The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2025 payable on August 15, 2025 to all shareholders of record as of July 25, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more

      7/1/25 8:34:00 AM ET
      $GEHC
      Medical Electronics
      Health Care
    • GE HealthCare reports first quarter 2025 financial results

      Revenue growth was 3% year-over-year; Organic revenue growth* was 4% Net income margin was 11.8% versus 8.0% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 15.0% versus 14.7% Diluted earnings per share (EPS) were $1.23 versus $0.81 for the prior year; Adjusted EPS* was $1.01 versus $0.90 Cash flow from operating activities was $250 million versus $419 million for the prior year; Free cash flow* was $98 million versus $274 million Updates full-year 2025 guidance Board of Directors authorizes a $1 billion share repurchase program GE HealthCare (NASDAQ:GEHC) today reported financial results for the first quarter ended March 31, 2025. GE He

      4/30/25 6:20:00 AM ET
      $GEHC
      Medical Electronics
      Health Care

    $GEHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • GE HealthCare upgraded by UBS with a new price target

      UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $73.00

      5/5/25 8:34:55 AM ET
      $GEHC
      Medical Electronics
      Health Care
    • GE HealthCare upgraded by Goldman with a new price target

      Goldman upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00 from $85.00 previously

      3/11/25 7:35:30 AM ET
      $GEHC
      Medical Electronics
      Health Care
    • GE HealthCare upgraded by Jefferies with a new price target

      Jefferies upgraded GE HealthCare from Hold to Buy and set a new price target of $103.00 from $95.00 previously

      1/8/25 7:50:38 AM ET
      $GEHC
      Medical Electronics
      Health Care

    $GEHC
    SEC Filings

    See more
    • GE HealthCare Technologies Inc. filed SEC Form 8-K: Leadership Update

      8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

      7/24/25 4:33:29 PM ET
      $GEHC
      Medical Electronics
      Health Care
    • GE HealthCare Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

      6/9/25 4:07:02 PM ET
      $GEHC
      Medical Electronics
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by GE HealthCare Technologies Inc.

      SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

      6/6/25 11:26:39 AM ET
      $GEHC
      Medical Electronics
      Health Care

    $GEHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jimenez Frank R bought $100,624 worth of shares (1,315 units at $76.52), increasing direct ownership by 2% to 75,796 units (SEC Form 4)

      4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

      5/2/24 6:00:38 AM ET
      $GEHC
      Medical Electronics
      Health Care

    $GEHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

      SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

      11/12/24 12:53:28 PM ET
      $GEHC
      Medical Electronics
      Health Care
    • Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

      SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

      10/22/24 4:16:16 PM ET
      $GEHC
      Medical Electronics
      Health Care
    • SEC Form SC 13G/A filed by GE HealthCare Technologies Inc. (Amendment)

      SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

      4/2/24 4:07:29 PM ET
      $GEHC
      Medical Electronics
      Health Care